ClinicalTrials.gg
CompletedNCT00824954Updated Nov 17, 2026

Extracorporeal Photopheresis in Children and Young Adults With Refractory Acute Graft Versus Host Disease

A Phase 2 interventional study of ECP (performed on Themos UVAR-XTS or external UVA irradiator after cell collection by apheresis) in Graft Versus Host Disease, sponsored by University Hospital, Clermont-Ferrand. Completed at 1 site in France. Open to participants aged 0 Years to 30 Years. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by University Hospital, Clermont-Ferrand · Phase 2, Interventional, and Treatment

How we know · 2 judgments

Updated Nov 17, 2026Now CompletedResults publication added+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
0 Years to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 54 studies in Graft vs Host Disease with a site in France — 10 open to participants now, 14 under way, 4 of them phase 3. Graft vs Host Disease · France.

Enrollment
37th of 47
30 · median 65
Started
2009
with 1 other
Phase 2
16 of 54
4 open now
Registered
6th of 54
by date
Lead sponsor
3 of 54
University Hospital, Clermont-Ferrand

Among the 54 studies in Graft vs Host Disease with a site in France, this one is the 37th largest by enrollment of the 47 interventional ones that give a count, is one of 2 that started in 2009, is one of 16 in phase 2, and was the 6th registered.

Graft vs Host Disease

804 studies on the registry are indexed under Graft vs Host Disease; 147 are open to participants now.

Browse Graft vs Host Disease studies →

Open to participants now

10 of the 54 studies in Graft vs Host Disease with a site in France are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 101 Graft vs Host Disease studies recruiting now, 51 (50%) set no upper age limit and 40 (40%) stop at 75 or younger; 42 take children under 18; 9 take healthy volunteers.

This study: 0 Years to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 54 studies in Graft vs Host Disease with a site in France, or all of them as a file.
02

Study summary

Purpose : to evaluate the efficacy of ECP in children with refractory acute GVHD This study addresses patients with persistent GVHD after steroid and/or monoclonal antibody therapy

Read the detailed description

One arm. Six sessions in two weeks. Classification in complete response (resolution of all signs of GVHD), partial response (improvement of at least one grade) or absence of response (Glucksberg criteria). Tapering depending on patient condition during weeks 2 to 10. Final evaluation at week 10. Steroid therapy tapering at the discretion of the investigator.

03

Conditions studied

  • Graft Versus Host Disease

Browse trials for

Keywords

  • 0 to 30 years
  • Refractory Acute GVHD
04

Who can participate

Ages eligible
0 Years to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 0 to 30 years
  • Acute to (disease progression after 2 days or absence of response after 4 days) and/or therapy (absence of response after 8 days)
  • patient consent and/or parent consent

Exclusion criteria

Exclusion Criteria:

  • less of 10 kgs BW
  • clinical or biological state precluding the apheresis
  • previous therapy with anti-lymphocyte serum (excepted in the conditioning regimen)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Enrollment
30 participants (actual)

Interventions

  • ProcedureECP (performed on Themos UVAR-XTS or external UVA irradiator after cell collection by apheresis)

    ECP (performed on Thermos UVAR-XTS or external UVA irradiator after cell collection by apheresis)

06

What researchers measure

Primary outcomes

  1. GVHD grading

    Time frame: during weeks 2 to 10

Secondary outcomes

  1. Overall survival Incidence of chronic GVHD

    Time frame: during weeks 2 to 10

07

Study locations

1 site
  • CHU Clermont-Ferrand
    Clermont-Ferrand, 63000, France
08

References and documents

Publications

  • Sauret A, Rabiau N, Rochette E, Greze V, Halle P, Ouachee M, Dalle JH, Seror E, Serraz D, Yakouben K, Adjaoud D, Pagnier A, Marie-Cardine-Bobbia A, Oudot C, Curtillet C, Poiree M, Kanold J, Merlin E. Shortened apheresis-based extra-corporeal photochemotherapy for acute refractory GVHD in children: a prospective study. Bone Marrow Transplant. 2016 Jun;51(6):866-8. doi: 10.1038/bmt.2016.11. Epub 2016 Feb 8. No abstract available. PubMed 26855157 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2009 to primary completion in Jan 2014, 55 months.

Of 86 non-industry phase 2 interventional studies under Graft vs Host Disease, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 116. This study's 55 months is close to that.

Counting every sponsor, half of 103 studies reached it within 52 months; a quarter within 29 and three quarters within 87.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Jun 2012 → Jan 2014 and completion Dec 2012 → Dec 2014.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2008
First posted
Jan 19, 2009
StartActual
Jun 2, 2009
Primary completionActual
Jan 31, 2014was Jun 2012
CompletionActual
Dec 15, 2014was Dec 2012
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Completed
changed Nov 17, 2026
Primary completion
Jun 2012→Jan 31, 2014 (actual)
Nov 17, 2026
Study completion
Dec 2012→Dec 15, 2014 (actual)
Nov 17, 2026
Eligibility
Minimum age none→0 Years
Nov 17, 2026
Publications
Results publication added: Sauret A, Rabiau N, Rochette E, Greze V, Halle P, Ouachee M, Dalle JH, Seror E, Serraz D, Yakouben K, Adjaoud D, Pagnier A, Marie-Cardine-Bobbia A, Oudot C, Cu… PubMed 26855157 ↗
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Status unknown→Completed
    Publications Results publication added: Sauret A, Rabiau N, Rochette E, Greze V, Halle P, Ouachee M, Dalle JH, Seror E, Serraz D, Yakouben K, Adjaoud D, Pagnier A, Marie-Cardine-Bobbia A, Oudot C, Cu… PubMed 26855157 ↗
    Primary completion Jun 2012→Jan 31, 2014 (now actual)
    Study completion Dec 2012→Dec 15, 2014 (now actual)
    Eligibility Minimum age none→0 Years
    + 4 other changes: responsible party, design details, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT00824954
Responsible party
Sponsor
First posted
Jan 19, 2009
Start date
Jun 2, 2009
Primary completion
Jan 31, 2014
Completion
Dec 15, 2014
Last update
Nov 17, 2026

Study contacts

Etienne Merlin
principal investigator · University Hospital, Clermont-Ferrand
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion